-
Scientists have made new achievements in the field of cancer metabolism!
Time of Update: 2020-09-29
In !-- article, we've compiled and shared recent scientific achievements in the field of cancer metabolism research! Photo Credit: University of California San Diego 1 Nature: How can you effectively
-
Nat Commun: New antibodies help to meddle SARS-Cov-2 virus infection.
Time of Update: 2020-09-29
Dr. Yang Wang, author of the article, and colleagues described the characteristics of monoclonal antibodies (MABs) that cross-react against SARS-CoV-2 prickly proteins, suggesting that blocking the binding of ACE2 subjects to respiratory mucous membrane tissue may prevent or limit SARS-CoV-2 infections that cause COVID-19 disease.
-
Multiple articles focus on new advances in the study of autoimmune diseases!
Time of Update: 2020-09-29
In !-- article, we've compiled a number of research results to focus on scientists' new achievements in the field of autoimmune disease research and share them with you! Photo Credit: Frontiers 1 PNAS
-
Scientists have made new achievements in the field of neutral granulocyte research!
Time of Update: 2020-09-29
!-- webeditor:page title" -- In this article, we compiled several important research results to jointly interpret the new achievements made by scientists in the field of neutral granulocyte research a
-
In recent years, scientists have made new achievements in the field of proteomics research!
Time of Update: 2020-09-29
In !-- paper, we have compiled several important research results to interpret the new achievements made by scientists in the field of proteomics research in recent years! Share it with everyone! Phot
-
Cell: Patients with asymptomatic or mild COVID-19 recovery produce a strong T-cell immune response.
Time of Update: 2020-09-29
21, 2020 /--- In a new study, researchers from sweden's Karolinska Institute report that mild COVID-19 triggers a strong memory T-cell response, even in the absence of detectable virus-specific antibody responses.
-
Recent scientific achievements in the field of stomach cancer research!
Time of Update: 2020-09-29
In a new study, researchers from Chiba University in Japan, the Singapore Science and Technology Research Agency and Duke-Singapore National University revealed a new pattern of EBV-related stomach cancer, in which the EBV virus genome directly alters the host's metastatic genetic landscape, promoting the activation and tumor development of proto-oncogene, a gene involved in normal cell growth that can become carcinogenic when mutated.
-
New medicine for rare diseases! Novart's first supplement factor B inhibitor LNP023 treatment of hairy nocturnal hemoglobinuria (PNH) shows strong efficacy!
Time of Update: 2020-09-28
The results, published at the meeting, showed that LNP023, as an additional therapy for Soliris, significantly improved hematological response and increased hemoglobin levels in PNH patients who were still active in hemolysis, anemia, and needed infusion of red blood cells, although treated with the supplement C5 inhibitor Soliris (eculizumab).
-
Recent important results to interpret new advances in cancer stem cell research!
Time of Update: 2020-09-28
Because it's a mixture, no drug is effective at targeting it; in a recent study published in the international journal Scientific Reports, scientists from the University of Houston and others found a new biomarker in cancer stem cells that could actually direct the survival and spread of cancer, and the results could potentially help researchers develop new drugs to target cancer stem cells, thereby curbing cancer progression.
-
GlaxoSmithKline/Vir launches phase 2/3 clinical trial of new coronary and antibody.
Time of Update: 2020-09-28
Recently, Vir Biotechnology and GlaxoSmithKline (GSK) announced that the new coronavirus and antibody VIR-7831 (also known as GSK4182136) jointly developed by the two companies have completed the first patient in phase 2/3 clinical trials.
-
"Reduce damage and strengthen repair"! The treatment of multiple sclerosis (RMS) in the treatment of Peposia has long-term efficacy and safety!
Time of Update: 2020-09-28
September 02, 2020 // -- BMS recently announced the new drug Zeposia (100) for multiple sclerosis at the 8th Joint ACTRIMS-ECTRIMS Conference of msVirtual 2020 Conference The interim results of the Ozanimod 3 open label extension trial DAYBREAK confirmed Zeposia's long-term efficacy and safety in patients with multiple sclerosis (RMS): most patients did not relapse during the 24th and 36th months of treatment and did not have new safety issues.
-
Science: Chinese scientists have revealed that foam-assisted T cells expressing SOSTDC1 promote bubble-regulating T-cell differentiation.
Time of Update: 2020-09-28
study was published in the August 21, 2020 issue of the Journal of Science under the title "SOSTDC1-producing follicular helper T cells promote regulatory follicular cell cell solution." images from Science, 2020, doi:10.1126/science.aba6652.
-
Highlights of HIV research in August 2020.
Time of Update: 2020-09-28
1008679 In a new study, Rachel Resop, a postdoctoral researcher at George Washington University in the United States, and Alberto Bosque, an assistant professor, and colleagues found that as an approved immunomodulation drug for multiple sclerosis, fingolimod (FTY720) blocks hiv infection and transmission in human immune cells.
-
Australian study finds severe viral infection can quickly 'paralyze' T-cells
Time of Update: 2020-09-28
Severe infections caused by viruses, such as HIV or neocooptovirus, can quickly "paralyze" immune cell T cells, and improving the activity of T-cells in response to the mechanisms could help improve antiviral and cancer therapies, according to a new Australian study.
-
Science: Significant progress! Enterococcal phage can enhance the efficacy of cancer immunotherapy.
Time of Update: 2020-09-28
study was published in the August 21, 2020 issue of the Journal of Science under the title "Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage." from Science, 2020, doi:10.1126/science.aax0701.
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.
-
Science Sub-Journal: The new COVID-19 hybrid test method can efficiently and highly flux detection of asymptomatic carriers.
Time of Update: 2020-09-28
study was recently published in the journal Science Advances under the title "Efficient high-doesn't SARS-CoV-2 testing to detect asymptomatic carriers." P-BEST design and testing of 384 samples with a positive carrying rate of 1%, pictured is Science Advances, 2020, doi:10.1126/sciadv.abc5961.
-
JCI: Exocystopic tissue host T cells survive hematopoietic stem cell transplantation and promote graft resistance to host disease.
Time of Update: 2020-09-28
study was recently published in the journal Journal of Clinical Investigation under the title "Perseon host T cells survive hematopotic stem cellation and promote graft-versus-host disease".
-
Science: Explaining previous Zika virus infections can increase the risk of severe dengue virus infection.
Time of Update: 2020-09-28
Leah Katzelnick, lead author of the paper and a postdoctoral scholar at the University of California, Berkeley School of Public Health, said, "The key issue that our study identifies is that previous infections with the Zika virus do significantly increase your risk of developing symptomatic and more severe dengue fever." the findings raise the question: Will vaccines targeting the Zika virus increase people's risk of more severe dengue fever?
-
Science: Reveals the mechanism by which protein BTN3A1 regulates anti-tumor immune response.
Time of Update: 2020-09-28
they found that CD277-specific antibodies converted BTN3A1 from immunosuppressive molecules into immunostatification molecules, dynamically inducing coordinated anti-tumor immune responses driven by alpha beta T cells and gamma T cells, thereby preventing the progression of ovarian cancer.
-
The first new mechanism acne drug in 40 years! Local androgen inhibitor Winlevi emulsion approved by FDA!
Time of Update: 2020-09-28
Winlevi is the first FDA-approved acne drug with a new mechanism of action (MOA) in nearly 40 years, providing dermatologists and patients with a new and effective treatment.
